patent.fyi
Applications  /  US 2026/0355138
United States Patent Application Publication

US 2026/0355138 A1

Published
Nov 12, 2026
Filed
Jun 11, 2026
Earliest date on the face
Dec 11, 2023
Classification
A61K 31/192
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Intermittent cooling for pain relief

What ifWhat if a circulating-water pad provides pain relief by cooling tissue around the surgical site?
Claim language“anti-inflammatory analgesic”

A pump circulates chilled water through channels in a flexible pad placed over a dry insulating layer. Intermittent cooling lowers superficial tissue temperature and slows sensory nerve conduction.

1.2External support limits muscle loading

What ifWhat if an external brace limits the movement that triggers painful muscle guarding?
Claim language“muscle relaxant”

A padded brace uses adjustable straps and rigid stays to restrict movement at the affected joint. Restricting joint excursion limits stretch and loading of nearby muscles during repositioning.

1.3Electrical stimulation modulates sensory input

What ifWhat if surface electrodes deliver electrical pulses to modulate neuropathic pain?
Claim language“neuropathic analgesic”

A battery-powered pulse generator sends biphasic pulses through two electrodes placed on intact skin near the painful area. The pulses recruit sensory afferents that modulate the transmission of pain signals in the spinal cord.

1.4Pressure redistribution during repositioning

What ifWhat if a contoured support reduces contact pain by shifting pressure away from the tender area?
Claim language“amount of anesthetic”

A contoured foam support has a recessed region aligned with the tender site. The surrounding foam spreads the load over a larger area and reduces direct pressure at the site during repositioning.

1.5Hollow needles deliver below skin

What ifWhat if a hollow microneedle array deposits the analgesic in superficial skin from a sterile aqueous solution?
Claim language“a carrier having skin penetration enhancement qualities”

A shallow array of hollow needles makes physical channels through the stratum corneum. A metering chamber drives the solution through the needle lumens and into the superficial dermis.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Periarticular gel for physical rehabilitation

An outpatient rehabilitation formulation retains the anti-inflammatory analgesic, muscle relaxant, neuropathic analgesic, and local anesthetic for use at a site of nonsurgical musculoskeletal pain. The four agents are dispersed in a hydroxyethyl cellulose gel containing propylene glycol as a skin penetration enhancer. The gel spreads over intact skin near the affected joint, and the vehicle releases the dispersed agents at the skin surface.

Component substitution

Diclofenac in a hydroalcoholic gel

Diclofenac sodium replaces ketoprofen as the anti-inflammatory analgesic, alongside baclofen, amitriptyline, and lidocaine. A hydroxypropyl cellulose network thickens a water, ethanol, and propylene glycol vehicle that holds the four agents. Ethanol and propylene glycol enhance skin penetration, and the polymer limits runoff after spreading.

Lipid vesicles as the penetration carrier

A suspension of phosphatidylcholine vesicles replaces the emulsion carrier and retains the anti-inflammatory analgesic, muscle relaxant, neuropathic analgesic, and local anesthetic. Water-soluble forms are introduced during hydration of the lipid film, and lipid-soluble forms are incorporated into the film before hydration. The vesicle suspension is blended into a hydroxyethyl cellulose gel, and the phospholipids interact with the outer skin layer as the agents partition out of the vehicle.

Parameter or scale variation

Two film thicknesses for release testing

The same batch containing all four active agents and the penetration-enhancing carrier is spread through 100 and 200 micrometer spacers over separate 4 square centimeter test membranes. The spacers produce nominal wet film volumes of 40 and 80 microliters. The two films use the same membrane material and receptor fluid so that the measured release profiles reflect the difference in applied film thickness.

Combination with existing systems

Four-agent gel in a reservoir patch

A flexible reservoir patch holds the four active agents in a propylene glycol-containing gel between a sealed backing and a skin-facing porous membrane. A perimeter adhesive ring secures the patch to intact skin and keeps the adhesive separate from the gel reservoir. The agents diffuse through the membrane to the skin, where the carrier promotes penetration.

Automated or data-driven variant

Gravimetric filling with feedback control

A positive-displacement pump transfers the mixed four-agent formulation and its penetration-enhancing carrier from an agitated vessel into single-use containers on a load cell. The controller tares each empty container, fills rapidly to a preset fraction of the target mass, and then pulses the pump to reach the target. The controller records each net fill mass and diverts containers outside the configured mass tolerance.

Specific version of a part

Diclofenac sodium in aqueous gel

Diclofenac sodium is dissolved in the aqueous phase of a carbomer gel. Diclofenac inhibits cyclooxygenase activity and reduces prostaglandin production in exposed tissue.

Baclofen in a cellulose gel

Micronized baclofen is dispersed in a hydrated hydroxyethyl cellulose gel. Baclofen activates gamma-aminobutyric acid type B receptors and reduces excitatory transmission in spinal motor pathways.

Lidocaine base in an emulsion

Lidocaine base is dissolved in the oil phase of an oil-in-water cream. Lidocaine blocks voltage-gated sodium channels in exposed sensory nerve fibers and suppresses impulse conduction.

Ethanol and propylene glycol carrier

The carrier uses water, ethanol, and propylene glycol as a mixed solvent system. Ethanol alters lipid packing in the stratum corneum, and propylene glycol maintains drug solubility as ethanol evaporates.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 9,707,197 B2
Published
Jul 18, 2017
Filed
Aug 29, 2016
Class
A61K 31/197
Document BUS 11,471,427 B1
Published
Oct 18, 2022
Filed
Jul 26, 2019
Class
A61K 31/122
Claim 1
Document A
Document B
1.1an amount of anti-inflammatory analgesic;
The composition comprises 0.5% to 10% by weight of a neuropathic analgesic; 0.5% to 10% by weight of a muscle relaxant; 0.5% to 20% by weight of an anti-inflammatory analgesic; and 0.5% to 10% by weight of an anesthetic.
A · US 9,707,197 B2 · abstract
According to further aspects of the present teaching, the topical treatment medicinal composition further includes a topical nonsteroidal anti-inflammatory drug, wherein the nonsteroidal anti-inflammatory drug is selected from the group consisting of diclofenac/misoprostol systemic, capsaicin/diclofenac topical, trolamine salicylate, naproxen, ibuprofen, aspirin and combinations thereof.
B · US 11,471,427 B1 · ¶ 37
1.2an amount of muscle relaxant;
The composition comprises 0.5% to 10% by weight of a neuropathic analgesic; 0.5% to 10% by weight of a muscle relaxant; 0.5% to 20% by weight of an anti-inflammatory analgesic; and 0.5% to 10% by weight of an anesthetic.
A · US 9,707,197 B2 · abstract
1.3an amount of neuropathic analgesic;
The composition comprises 0.5% to 10% by weight of a neuropathic analgesic; 0.5% to 10% by weight of a muscle relaxant; 0.5% to 20% by weight of an anti-inflammatory analgesic; and 0.5% to 10% by weight of an anesthetic.
A · US 9,707,197 B2 · abstract
The Henna plant contains a chemical compound 2-hydroxy-1,4-naphthoquinone within its leaves. This compound is believed to possesses natural analgesic and skin cooling properties that when combined with other natural and synthetic compounds creates an efficacious and safe, non-opioid topical therapy for those suffering from HFS as well as other painful skin diseases and neurological conditions.
B · US 11,471,427 B1 · ¶ 64
1.4an amount of anesthetic; and
While usually palliative care or supportive treatment along with topical anesthetics is used to treat HFS, a study has found that topically applying Henna to the affected areas can be effective in providing relief from this side-effect.[6]
B · US 11,471,427 B1 · ¶ 22
1.5a carrier having skin penetration enhancement qualities.

An empty cell means only that no passage was reproduced there.

Statements in these documents
Treatment of musculoskeletal pain using anti-inflammatory drugs, such as non-steroidal anti-inflammatory drugs or NSAIDs, is not always effective.
A · US 9,707,197 B2 · ¶ 3
Forming another aspect of the invention, the neuropathic analgesic can be Amitriptyline, the muscle relaxant can be Baclofen, the anesthetic can be Lidocaine and the anti-inflammatory analgesic can be Ketoprofen.
A · US 9,707,197 B2 · ¶ 9
The medicinal composition may also be used for treating other skin ailments.
B · US 11,471,427 B1 · ¶ 1
Frustrated with the lack of options and unsatisfied with the relief she felt with prescription and OTC remedies, we created a topical formulation which, when applied once a day, cooled the skin and routinely reduced her pain score by 75% over the span of 24 weeks.
B · US 11,471,427 B1 · ¶ 3
Cite aspatent.fyi, US 2026/0355138 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355138/, SHA-256 8da963b78f092a992866d878fb1ba0d68ab9be088e4703f23212d32748fd6f3f
First published
Permanent addresshttps://patent.fyi/US20260355138/
Content fingerprint (SHA-256)8da963b78f092a992866d878fb1ba0d68ab9be088e4703f23212d32748fd6f3f
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi